Abstract:Background Familial hypertrophic cardiomyopathy (HCM) is the most common genetic cardiovascular disease. Related mutations contributing to hypercontractility and poor relaxation in HCM have been incompletely understood. The purpose of this study was to explore and verify a novel variant in cardiac myosin-binding protein C3 (MYBPC3) in a HCM family. Methods Clinical information was collected and cardiac evaluation was performed in the pedigree. Second-generation sequencing technology was used to investigate the proband and his family. Computational prediction of mutation effects at genomic level and 3D visualization of the mutated protein were achieved by in silico analysis. Results Typical interventricular septal thickening was detected in all the four HCM patients. A c.1042\_1043insCGGCA mutation of MYBPC3 was verified in the proband and family members. Mild phenotype associated with delayed onset and relative favorable prognosis were observed in the pedigree. In silico analysis of the mutation revealed that c.1042\_1043insCGGCA led to an early termination of MYBPC protein synthesis at C2 domain, losing the domains that are essential for myosin-and titin-binding. Conclusion The novel c.1042_1043insCGGCA mutation of MYBPC3 was a genetic basis for HCM. Our gene sequence based computational analysis predicted the pathogenicity of the mutation by correlating MYBPC3 genotypes with clinical phenotypes. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement Yes ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the First Affiliated Hospital of Zhejiang University. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes All relevant data are within the manuscript and its Supporting Information files.

A rare form of LIM domain‐binding protein 3 (LDB3) mutation causes hypertrophic cardiomyopathy and myofibrillar myopathy type 4

Case Report: Novel LIM Domain-Binding Protein 3 (LDB3) Mutations Associated with Hypertrophic Cardiomyopathy Family

Inhibition of HSC70 Alleviates Hypertrophic Cardiomyopathy Pathology in Human Induced Pluripotent Stem Cell‐derived Cardiomyocytes with a MYBPC3 Mutation

The Novel Mitochondrial 16S Rrna 2336T>C Mutation is Associated with Hypertrophic Cardiomyopathy

Limb Girdle Muscular Dystrophy 23 Caused by Compound Heterozygous Mutations of LAMA2 Gene

Identification of a LMNA (c.646c > T) Variant by Whole-Exome Sequencing in Combination with a Dilated Cardiomyopathy (DCM) Related Gene Filter in a Family with Familiar DCM

Identification of three novel pathogenic mutations in sarcomere genes associated with familial hypertrophic cardiomyopathy based on multi-omics study

An alpha-helix variant p.Arg156Pro in LMNA as a cause of hereditary dilated cardiomyopathy: genetics and bioinfomatics exploration

A Novel Truncating Variant in MYBPC3 Causes Hypertrophic Cardiomyopathy

The <i>LMNA </i>p.R541C mutation causes dilated cardiomyopathy in human and mice

A pathogenic nonsense mutation (c.1522C>T) of the MYBPC3 gene is implicated with hypertrophic cardiomyopathy

TBX20 Loss-of-function Mutation Associated with Familial Dilated Cardiomyopathy.

Whole-exome sequencing identifies rare compound heterozygous mutations in the MYBPC3 gene associated with severe familial hypertrophic cardiomyopathy.

Gender- and Age-Related Differences in Distinct Phenotypes of Hypertrophic Cardiomyopathy-Associated Mutation MYBPC3–E334K

TBX5 Loss-of-function Mutation Contributes to Familial Dilated Cardiomyopathy

Young and Early‐onset Dilated Cardiomyopathy with Malignant Ventricular Arrhythmia and Sudden Cardiac Death Induced by the Heterozygous LDB3, MYH6, and SYNE1 Missense Mutations

Exome Sequencing Identifies a Novel MYH7 P.g407c Mutation Responsible for Familial Hypertrophic Cardiomyopathy

GATA4 Loss-of-function Mutation Underlies Familial Dilated Cardiomyopathy.

A Novel Tbx20 Loss-Of-Function Mutation Contributes to Adult-Onset Dilated Cardiomyopathy or Congenital Atrial Septal Defect

Human disease-causing mutations result in loss of leiomodin 2 through nonsense-mediated mRNA decay

Novel familial dilated cardiomyopathy mutation in MYL2 affects the structure and function of myosin regulatory light chain